Brinkman Mary Beth, Fan Kaili, Shiveley Renee L, Van Anglen Lucinda J
College of Pharmacy, University of Houston, Houston, TX, USA.
Ann Pharmacother. 2012 Jun;46(6):e15. doi: 10.1345/aph.1Q331. Epub 2012 May 22.
To report a case of multidrug-resistant osteomyelitis successfully treated with telavancin, rifampin, and meropenem.
An 18-year-old male with spina bifida was treated primarily in the outpatient setting over the course of 133 days with multiple antimicrobials for a recurrent right calcaneal wound and osteomyelitis infection. Initial cultures were positive for methicillin-resistant Staphylococcus aureus and coagulase-negative Staphylococcus, which were treated with intravenous vancomycin 1 g every 12 hours, increased after 13 days to 1.5 g every 12 hours with addition of rifampin 300 mg twice daily, both of which were discontinued on day 22 due to leukopenia (white blood cell count 3.0 × 10(3)/μL) and neutropenia (absolute neutrophil count 0.2 × 10(3)/μL). Daptomycin 8 mg/kg/day was then initiated with rifampin 300 mg twice daily; treatment was discontinued after 49 days due to an elevated creatine kinase level of 1831 U/L (baseline 86). Intravenous meropenem 1 g every 8 hours was again initiated on day 83 following additional identification of quinolone-resistant Pseudomonas aeruginosa from the soft tissue of the right foot. Intravenous vancomycin 1 g every 12 hours was also restarted at this time for persistent coagulase-negative Staphylococcus and oral rifampin 300 mg twice daily was again added. Adverse events again required the discontinuation of vancomycin on day 91. The eventual drug therapy regimen consisted of telavancin 750 mg/day for 42 days, meropenem for 50 days, and oral rifampin for 50 days. At the end of treatment, the patient's right heel wound had almost completely closed. He was without recurrence or treatment-related adverse events at follow-up 1 year later.
Antimicrobial selection for osteomyelitis infections presents a challenge to the clinician due to patient intolerance, increasing antimicrobial resistance, and variable antimicrobial penetration at the site of infection. To our knowledge, this is the first case report of the successful use of a regimen including telavancin for the treatment of a recurrent, coagulase-negative Staphylococcus osteomyelitis infection.
In this complex case involving a polymicrobial infection of the right calcaneal bone and surrounding soft tissue, eventual drug therapy including telavancin, meropenem, and rifampin resulted in a successful clinical response.
报告1例采用特拉万星、利福平及美罗培南成功治疗的耐多药骨髓炎病例。
一名18岁患有脊柱裂的男性患者,因右跟骨伤口复发及骨髓炎感染,在门诊接受了133天的多种抗菌药物治疗。初始培养结果显示耐甲氧西林金黄色葡萄球菌和凝固酶阴性葡萄球菌呈阳性,最初每12小时静脉注射1g万古霉素进行治疗,13天后增至每12小时1.5g,并加用利福平每日2次、每次300mg,二者均在第22天因白细胞减少(白细胞计数3.0×10³/μL)和中性粒细胞减少(绝对中性粒细胞计数0.2×10³/μL)而停用。随后开始使用达托霉素8mg/kg/天并联合利福平每日2次、每次300mg;49天后因肌酸激酶水平升高至1831U/L(基线86)而停药。在从右脚软组织中额外鉴定出喹诺酮耐药铜绿假单胞菌后,于第83天再次开始每8小时静脉注射1g美罗培南。此时也重新开始每12小时静脉注射1g万古霉素以治疗持续存在的凝固酶阴性葡萄球菌,并再次加用口服利福平每日2次、每次300mg。不良事件再次导致在第91天停用万古霉素。最终的药物治疗方案包括使用特拉万星750mg/天,持续42天;美罗培南,持续50天;口服利福平持续50天。治疗结束时,患者右足跟伤口几乎完全愈合。1年后随访时,患者无复发及与治疗相关的不良事件。
由于患者耐受性、抗菌药物耐药性增加以及感染部位抗菌药物渗透情况各异,骨髓炎感染的抗菌药物选择对临床医生而言是一项挑战。据我们所知,这是首例成功使用包括特拉万星的方案治疗复发性凝固酶阴性葡萄球菌骨髓炎感染的病例报告。
在这例涉及右跟骨及周围软组织多重微生物感染的复杂病例中,最终包括特拉万星、美罗培南和利福平的药物治疗取得了成功的临床疗效。